Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 15;23(22):6764-6770.
doi: 10.1158/1078-0432.CCR-17-0019. Epub 2017 Jun 29.

Immunotherapy of Prostate Cancer: Facts and Hopes

Affiliations
Review

Immunotherapy of Prostate Cancer: Facts and Hopes

Marijo Bilusic et al. Clin Cancer Res. .

Abstract

In the last few years, immunotherapy has become an important cancer treatment modality, and although the principles of immunotherapy have evolved over many decades, the FDA approvals of sipuleucel-T and ipilimumab began a new wave in immuno-oncology. Despite the current enthusiasm, it is unlikely that any of the immunotherapeutics alone can dramatically change prostate cancer outcomes, but combination strategies are more promising and provide a reason for optimism. Several completed and ongoing studies have shown that the combination of cancer vaccines or checkpoint inhibitors with different immunotherapeutic agents, hormonal therapy (enzalutamide), radiotherapy (radium 223), DNA-damaging agents (olaparib), or chemotherapy (docetaxel) can enhance immune responses and induce more dramatic, long-lasting clinical responses without significant toxicity. The goal of prostate cancer immunotherapy does not have to be complete eradication of advanced disease but rather the return to an immunologic equilibrium with an indolent disease state. In addition to determining the optimal combination of treatment regimens, efforts are also ongoing to discover biomarkers of immune response. With such concerted efforts, the future of immunotherapy in prostate cancer looks brighter than ever. Clin Cancer Res; 23(22); 6764-70. ©2017 AACR.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Figures

Figure 1
Figure 1. Requirements for effective immunotherapy
A) Generation of immune response. Antigen-presenting cells process targeted antigens (green) and present them to T cells with major histocompatibility complexes (MHC) on their surface, along with costimulatory molecules. This complex stimulates T cells to become cytotoxic CD8+ T cells. B) Functional effector cells within the tumor. Activated cytotoxic T cells recognize targeted antigens on the surface of cancer cells and release cytotoxins such as perforin and granzymes, triggering caspases and apoptosis. In addition, activated T cells also express Fas ligands that bind to Fas receptors on tumor cells, also inducing apoptosis.

References

    1. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580–93. - PMC - PubMed
    1. Drake CG, Jaffee E, Pardoll DM, De Marzo AM, Platz EA, Sutcliffe S, et al. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81. - PubMed
    1. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256–69. - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22. - PubMed
    1. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2011;17:907–17. - PMC - PubMed